Trade Summary

2 weeks ago, Baker Bros. Advisors LP, serving as Dir, 10% owner at Kymera Therapeutics, Inc. (KYMR), purchased 2,005,813 shares at $86.00 per share, for a total transaction value of $172,499,918.00. Following this transaction, Baker Bros. Advisors LP now holds 7,955,916 shares of KYMR.

This purchase represents a 34.00% increase in Baker Bros. Advisors LP's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, December 11, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, December 11, 2025, meaning the disclosure happened on the same day as the trade.

Kymera Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.